ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO1116

Neutrophil/Lymphocyte Ratio in Prediction of Disease Progression in Patients with Stage 1-4 CKD in China: Results from the Chinese Cohort Study of CKD (C-STRIDE)

Session Information

Category: CKD (Non-Dialysis)

  • 1902 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Yuan, Qiongjing, Xiangya Hospital, Central South University, Changsha, China
  • Wang, Jinwei, Renal Division, Department of Medicine, Peking University First Hospital; Peking University Institute of Nephrology, Beijing, BEIJING, China
  • Xu, Hui, Nephrology Department, Xiangya Hospital, Central South University, Changsha, Hunan, China, ChangSha, China

Group or Team Name

  • the C-STRIDE study group

Chronic kidney disease (CKD) leads to end-stage renal failure and cardiovascular events. An attribute to these progressions is abnormalities in inflammation, which can be evaluated using the neutrophil/lymphocyte (N/L) ratio. We aimed to investigate the association of N/L ratio with the progression of ESKD, CVD and all-cause mortality in Chinese patients with stages 1-4 CKD.


A total of 1341 stages 1-4 CKD (18–74 years of age) patients with complete N/L and other relevant clinical variables were included in the current analysis. . Patients were divided according to the median of baseline N/L ratio (≥2.26 or <2.26). ESKD was defined at time to start hemodialysis, peritonal dialysis or renal transplantation. CVD risk was determined with onset of new CVD events. All-cause mortality was recorded at time of decease. The follow-up was censored at June 30, 2017. Cox regression analysis was used in estimating the association between N/L and the outcomes.


Baseline N/L ratio was related to anemia rate, total serum cholesterol, eGFR, blood pressure, uric acid, CKD-MBD rate, cardiovascular disease, ACR and metabolic acidosis. The study duration was 4.35 year(IQR 2.86-5.26). Patients with N/L ratio ≥2.26 were at risk of developing ESKD (HR 1.687(95% CI:1.288,2.209))and all-cause mortality (HR 3.220(95% CI:1.174,8.834))compared to patients with N/L ratio <2.26 (P<0.05); We did not observe a significant association between abnormal N/L and CVD risk in the multi-variable adjusted model.


Our results suggest that N/L ratio other than hs-CRP is associated with the risk of ESKD and all-cause mortality in Chinese patients with stage1-4 CKD. N/L ratio is an easily accessible and useful marker for monitoring CKD patients in clinical practice.


  • Government Support - Non-U.S.